HealthPolitics

STAT+: Amgen’s Repatha linked to fewer heart attacks

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/11/2026, 15:21:24 UTC.

Briefings

A biotech newsletter article reports that Amgen's Repatha is associated with fewer heart attacks compared to other treatments. The source states that Novartis has reported seven previously unreported cases of tumors in children receiving Zolgensma since 2019, totaling nine reports. The article invites readers to sign up for a biotech newsletter to stay updated on the science and politics driving biotech, but no specific data on Repatha's heart attack rates is provided.

Key points

• Novartis reported nine total tumor cases in children receiving Zolgensma since 2019, with seven being previously unreported.
• The article claims Repatha is linked to fewer heart attacks, but no specific statistics or comparative data are provided.

Context

This article discusses recent safety reports from Novartis regarding Zolgensma, a gene therapy for spinal muscular atrophy approved in 2019. It highlights a shift in reporting, noting seven new tumor cases since approval, and offers a biotech newsletter subscription as a way to follow the ongoing science and politics in the biopharma industry.

Limitations

The evidence is limited to a newsletter article that does not contain specific data on heart attack rates for Repatha. The source does not provide a direct comparison between Repatha and other treatments, nor does it offer a causal link between the treatments or the specific number of heart attacks.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 06/11/2026, 15:31:03 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieufxfzmjo64qk3ulhr4pf4yrsdl54sbg3l3flwjj5wqmahjkilvu